Skip to main content

Table 1 Baseline characteristics of the study population

From: The impact of age on the implementation of evidence-based medications in patients with coronary artery disease and its prognostic significance: a retrospective cohort study

Characteristic of patients

 

Age

 

Total N = 2830

< 60 years old N = 850

60–75 years old N = 1489

≤75 years old N = 491

p

 Age, yrs

64.62 ± 10.54

51.63 ± 6.37

67.48 ± 4.23

78.42 ± 2.93

< 0.001

 Gender, men, n (%)

575(20.32)

83(9.76)

370(24.85)

122(24.85)

< 0.001

 BMI, Kg/m2

24.20 ± 3.21

24.60 ± 2.95

24.12 ± 0.08

23.70 ± 0.17

< 0.001

 Smoking, n (%)

888(33.40)

331(40.91)

434(31.31)

123(26.51)

< 0.001

 Drinking, n (%)

647(24.80)

237(30.15)

320(23.49)

90(19.52)

< 0.001

Medical history

 Pre-hypertension, n (%)

1546(54.86)

357(42.20)

870(58.55)

319(65.64)

< 0.001

 Hyperlipidemia, n (%)

474(16.83)

169(19.98)

257(17.32)

48(9.86)

< 0.001

 Pre-diabetes mellitus, n (%)

622(22.08)

124(14.66)

378(25.47)

120(24.64)

< 0.001

Laboratory values

 LVEF, %

52.63 ± 23.07

51.26 ± 23.46

54.08 ± 22.01

50.49 ± 25.27

< 0.001

 eGFR, ml/min/1.73m2

80.39 ± 40.97

93.49 ± 63.63

76.29 ± 23.84

70.11 ± 22.25

< 0.001

 Total cholesterol, mmol/L

4.09 ± 1.14

4.21 ± 1.29

4.04 ± 1.09

4.02 ± 0.97

< 0.001

 LDL_C, mmol/L

2.40 ± 0.94

2.52 ± 1.06

2.36 ± 0.90

2.31 ± 0.81

< 0.001

 Blood glucose, mmol/L

7.03 ± 3.22

6.8 ± 3.04

7.05 ± 3.39

7.37 ± 2.98

0.010

Severity of CAD

 Number of stents, n

1.87 ± 1.11

1.77 ± 1.07

1.88 ± 1.11

2.05 ± 1.14

< 0.001

Diagnose

 Unstable angina, n (%)

1495(52.83)

422(49.65)

831(55.81)

242(49.29)

< 0.001

 STEMI, n (%)

392(13.85)

139(16.35)

179(12.02)

74(15.07)

0.010

 NSTEMI, n (%)

180(6.36)

40(4.71)

99(6.65)

41(8.35)

0.030

 All death, n (%)

270(9.54)

35(4.12)

143(9.60)

92(18.74)

< 0.001

 CV death, n (%)

150(5.30)

23(2.71)

76(5.10)

51(10.39)

< 0.001

Discharge medications

 Aspirin, n (%)

2608(92.16)

807(94.94)

1374(92.28)

427(86.97)

< 0.001

 Clopidogrel, n (%)

2522(89.12)

776(91.29)

1332(89.46)

414(84.32)

0.006

 Dual-antiplatelet, n (%)

2446(86.43)

761(89.53)

1288(86.50)

397(80.86)

< 0.001

 Statin, n (%)

2521(89.08)

778(91.53)

1307(87.78)

436(88.80)

0.023

 CCB, n (%)

744(26.29)

162(19.06)

433(29.08)

149(30.35)

< 0.001

 ACE inhibitors or ARBs, n (%)

1603(56.64)

436(51.29)

880(59.10)

287(58.45)

< 0.001

 Beta-receptor blockers, nw (%)

1874(66.22)

605(71.18)

990(66.49)

279(56.82)

< 0.001

  1. Data are expressed as means± SD or counts and percentages, as appropriate. Abbreviations: BMI: body mass index, DM: diabetes mellitus, LVEF: left ventricular ejection fraction, eGFR: estimated glomerular filtration rate, LDL-C: low-density lipoprotein-cholesterol, STEMI: ST-segment elevated myocardial infarction, NSTEMI: non-ST-segment elevated myocardial infarction, SD: standard deviation. ACE, angiotensin-converting enzyme; ARBs, angiotensin-receptor blockers